

Development of pan-KRAS Inhibitor Candidates for KRAS-Mutant Cancer Patients

Idience Co., Ltd.

idience

Precision Medicine Matters

ONCOLOGY	Candidate
Product Type	Small molecules
Indication	Cancer with KRAS mutation (pancreatic cancer, colon cancer, lung cancer)
Target	KRAS (Kirsten rat sarcoma virus)
MoA(Mechanism of Action)	pan-KRAS inhibitor
Competitiveness	<ol style="list-style-type: none"> 1. Effective across a wide range of KRAS mutations 2. Strong selectivity over wild-type KRAS, potentially contributing to improved safety 3. Robust and durable efficacy demonstrated in preclinical models 4. Favorable PK profile enabling once-daily oral administration 5. Differentiated profile supporting best-in-class positioning
Development Stage	Candidate
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.